Aceso Life Science Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Aceso Life Science Group şirketinin kazançları yıllık ortalama -6.9% oranında azalırken, Consumer Finance sektörünün kazançları yıllık 2% oranında artan oldu. Gelirler yıllık ortalama 15.8% oranında artan oldu.

Anahtar bilgiler

-6.9%

Kazanç büyüme oranı

0.9%

EPS büyüme oranı

Consumer Finance Sektör Büyümesi	-2.1%
Gelir büyüme oranı	15.8%
Özkaynak getirisi	-44.6%
Net Marj	-4,200.0%
Sonraki Kazanç Güncellemesi	28 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Feb 23

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Jan 01

Gelir ve Gider Dağılımı

Aceso Life Science Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SEHK:474 Gelir, gider ve kazançlar (HKD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Mar 24	11	-462	124
31 Dec 23	105	-441	124
30 Sep 23	198	-420	123
30 Jun 23	203	-342	125
31 Mar 23	207	-264	126
31 Dec 22	161	-301	134
30 Sep 22	115	-338	141
30 Jun 22	143	-354	147
31 Mar 22	170	-370	153
31 Dec 21	8	-197	162
30 Sep 21	-154	-25	171
30 Jun 21	-141	-200	188
31 Mar 21	-129	-376	204
31 Dec 20	-43	-523	209
30 Sep 20	43	-671	213
30 Jun 20	9	-477	201
31 Mar 20	-25	-284	189
31 Dec 19	48	-162	196
30 Sep 19	120	-40	203
30 Jun 19	148	-211	211
31 Mar 19	175	-381	219
31 Dec 18	200	-533	223
30 Sep 18	224	-686	226
30 Jun 18	237	-565	226
31 Mar 18	250	-445	227
31 Dec 17	235	-1,209	205
30 Sep 17	220	-1,972	183
30 Jun 17	169	-2,526	158
31 Mar 17	118	-3,079	133
31 Dec 16	95	-1,911	119
30 Sep 16	71	-743	106
30 Jun 16	57	-109	97
31 Mar 16	42	524	89
31 Dec 15	20	498	80
30 Sep 15	-1	471	70
30 Jun 15	-3	997	73
31 Mar 15	-5	1,523	75
31 Dec 14	6	1,281	79
30 Sep 14	17	1,039	82
30 Jun 14	22	466	80
31 Mar 14	26	-107	78
31 Dec 13	-13	-122	67

Kaliteli Kazançlar: 474 şu anda kârlı değil.

Büyüyen Kar Marjı: 474 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 474 kârlı değildir ve zararlar son 5 yılda yılda 6.9% oranında artmıştır.

Büyüme Hızlandırma: 474 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 474 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Consumer Finance sektörüyle ( -2.1% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 474 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -44.62% ) sahiptir.

Aceso Life Science Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Aceso Life Science Group Limited to Report First Half, 2025 Results on Nov 28, 2024

Full year 2024 earnings released: HK$0.064 loss per share (vs HK$0.036 loss in FY 2023)

Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Recent updates

Aceso Life Science Group Limited to Report First Half, 2025 Results on Nov 28, 2024

New minor risk - Share price stability

Insufficient new directors

Full year 2024 earnings released: HK$0.064 loss per share (vs HK$0.036 loss in FY 2023)

Aceso Life Science Group Limited, Annual General Meeting, Sep 19, 2024

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

New major risk - Revenue size

Aceso Life Science Group Limited Provides Group Earnings Guidance for the Six Months Ended 30 September 2023

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited to Report Fiscal Year 2023 Results on Jun 28, 2023

New minor risk - Market cap size

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

Aceso Life Science Group Limited Consolidated Earnings Guidance for the Six Months Ended 30 September 2022

Aceso Life Science Group Limited to Report First Half, 2023 Results on Nov 29, 2022

Aceso Life Science Group Limited (SEHK:474) agreed to acquire 4% stake in Quanzhou Donghai Bay Asset Management Company Limited for approximately CNY180 million.

Aceso Life Science Group Limited Announces Change of Company Secretary

Full year 2022 earnings released: HK$0.051 loss per share (vs HK$0.057 loss in FY 2021)

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Full year 2022 earnings released

Aceso Life Science Group Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Aceso Life Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2022

Senior Consultant recently bought HK$18m worth of stock

Senior Consultant recently bought HK$4.6m worth of stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Non-Executive Director Yao Li has left the company

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Senior Consultant recently sold HK$5.0m worth of stock

First half 2021 earnings released: HK$0.07 loss per share

New 90-day low: HK$0.23

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.07 loss per share

Aceso Life Science Group Limited to Report First Half, 2021 Results on Nov 25, 2020

New 90-day low: HK$0.28

Senior Consultant recently bought HK$852k worth of stock

Hao Tian Development Group Limited has completed a Follow-on Equity Offering in the amount of HKD 150 million.

Senior Consultant recently bought HK$2.8m worth of stock

New 90-day high - HK$0.34

Full year earnings released - HK$0.049 loss per share

Hao Tian Development Group Limited to Report Fiscal Year 2020 Results on Jun 29, 2020

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin